Skip to main content

Table 3 Combination therapy with the bypass pathway target

From: Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Target Representative compound* Structure Reference
MET Cabozantinib [145, 146]
MET Crizotinib [147]
MET Savolitinib [148]
FGFR AZD4547 [149]
ALK Lorlatinib [150]
ALK Brigatinib [151]
HER2 JQ1 [152]
HER2 Trastuzumab-DM1 [153]
BRAF V600E Encorafenib (LGX818) [64]
AURK B PF-03814735 [60, 154]
  1. *Osimertinib is a representative third-generation EGFR-TKI